Evidence map›Paper›PMID 32051535›Full record

ArticleBone marrow transplantation2020

Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation.

Kaito Harada, Shigeo Fuji, Sachiko Seo, Junya Kanda, Toshimitsu Ueki, Fumihiko Kimura, Koji Kato, Naoyuki Uchida, Kazuhiro Ikegame, Makoto Onizuka and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 18 institutions in 1 country.

Kaito HaradaDepartment of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan. k.harada@fuji.tokai-u.jp.ORCID http://orcid.org/0000-0002-8462-7550
Shigeo FujiDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University School of Medicine, Mibu, Japan.
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-6704-3633
Toshimitsu UekiDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Fumihiko KimuraDivision of Hematology, National Defense Medical College, Tokorozawa, Japan.ORCID http://orcid.org/0000-0001-6223-9904
Koji KatoDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
Kazuhiro IkegameDivision of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Makoto OnizukaDepartment of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
Ken-Ichi MatsuokaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Toshiro KawakitaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Yasushi OnishiDepartment of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.
Shingo YanoClinical oncology and Hematology, The Jikei University School of Medicine, Tokyo, Japan.
Takahiro FukudaHematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
Minoko TakanashiBlood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Masao OgataDepartment of Hematology, Oita University Hospital, Yufu, Japan.ORCID http://orcid.org/0000-0002-4896-5878
transplant complications working group of the Japan Society for Hematopoietic Cell Transplantation
Tokai University · JPNagano Red Cross Hospital · JPOita University Hospital · JPOsaka International Cancer Institute · JPDokkyo Medical University · JPHyogo Medical University · JPJapanese Red Cross Society, Japan · JPJichi Medical University · JPJikei University School of Medicine · JPKumamoto Medical Center · JPKyoto University · JPKyushu University · JPNational Defense Medical College · JPOkayama University Hospital · JPThe Japanese Data Center for Hematopoietic Cell Transplantation · JPTohoku University Hospital · JPTokyo Metropolitan Komagome Hospital · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graft failure (GF) is a life-threatening complication after allogeneic stem cell transplantation (SCT). Although salvage SCTs can be performed with haploidentical donor (HID) or cord blood (CB), no study has compared the performances of these two sources. Using nationwide registration data, we compared the transplant outcomes of patients who developed GF and underwent salvage transplantation from HID (n = 129) and CB (n = 570) from 2007 to 2016. The HID group demonstrated better neutrophil recovery (79.7 vs. 52.5% at 30 days, P < 0.001). With a median follow-up of 3 years, both groups demonstrated similar overall survival (OS) and nonrelapse mortality (NRM; 1-year OS, 33.1 vs. 34.6% and 1-year NRM, 45.1 vs. 49.8% for the HID and CB groups). After adjustments for other covariates, OS did not differ in both groups. However, HID was associated with a lower NRM (hazard ratio, 0.71; P = 0.038) than CB. The incidence of acute graft-versus-host disease (GVHD)-related deaths was significantly higher in the HID group, although infection-related deaths were observed more frequently in the CB group. HID may be a promising salvage SCT option after GF due to its faster engraftment and low NRM.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationFetal BloodHumansTransplantation Conditioning

Identifiers

PMID32051535
OpenAlexW3006581390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.